New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to relating to a number of respiratory treatments for chronic obstructive pulmonary disease (COPD) and a spacer device.
The proposal is a result of provisional agreements between PHARMAC and the local subsidiaries of GlaxoSmithKline (LSE: GSK), and Boehringer Ingelheim and a 2014 agreement between PHARMAC and Novartis (NOVN: VX).
In summary, from March 1, 2016, this proposal would result in:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze